Cholesterolosis
Methodology & AI Transparency ⓘ
Cholesterolosis Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: For patients presenting with Cholesterolosis (ICD-10-CM K82.4), Cholesterol, Triglycerides & Lipids protocols prioritize ApoB quantification [Cholesterolosis K82.4] paired with baseline and interval Fasting Triglycerides [Cholesterolosis K82.4] assessment.
- 2 Real-world patient consensus: Mapped to Cholesterol, Triglycerides & Lipids under ICD-10-CM K82.4 for Cholesterolosis clinical workups.
- 3 Typical cash cost range: Primary evaluation for Cholesterolosis incorporates ApoB quantification [Cholesterolosis K82.4] and symptom diary review.
- 4 Top reported side effects / signs: Longitudinal Cholesterolosis monitoring tracks Fasting Triglycerides [Cholesterolosis K82.4] toward < 100 mg/dL (K82.4).
Ask our AI Specialists anything about Cholesterolosis
What Is Cholesterolosis?
For patients presenting with Cholesterolosis (ICD-10-CM K82.4), Cholesterol, Triglycerides & Lipids protocols prioritize ApoB quantification [Cholesterolosis K82.4] paired with baseline and interval Fasting Triglycerides [Cholesterolosis K82.4] assessment.
Pathophysiology, Underlying Causes & Clinical Presentation
Mechanistic hallmarks of Cholesterolosis (K82.4) center on impaired hepatic LDL-receptor in Cholesterolosis (K82.4: clearance). targeted cholesterol & lipids interventions aim to normalize Fasting Triglycerides [Cholesterolosis K82.4].
Common Symptoms & Clinical Signs
- • Presentation of Cholesterolosis (K82.4): achilles tendon thickening, in Cholesterolosis (K82.4: xanthelasma, or premature)
- • Secondary Cholesterolosis clinical sign: coronary artery calcium [Cholesterolosis K82.4]
- • Symptom flares in Cholesterolosis correlating with Fasting Triglycerides [Cholesterolosis K82.4] deviation outside < 100 mg/dL (K82.4)
- • Functional cholesterol & lipids impact requiring ApoB quantification [Cholesterolosis K82.4] evaluation (K82.4)
Cholesterolosis Diagnostic Classification & Lab Markers
| Metric | Verified Benchmark | Source |
|---|---|---|
| ICD-10-CM Diagnostic Code | K82.4 | WHO / CMS ICD-10-CM Clinical Classification |
| Clinical Specialty Hub | Cholesterol, Triglycerides & Lipids | NLM Clinical Tables |
| Diagnostic / Lab Marker: Fasting Triglycerides [Cholesterolosis K82.4] | < 100 mg/dL (K82.4) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Lipoprotein(a) [Lp(a)] [Cholesterolosis K82.4] | < 75 nmol/L (K82.4) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Apolipoprotein B (ApoB) [Cholesterolosis K82.4] | < 70 mg/dL (< 55 mg/dL high risk) (K82.4) | Clinical Reference Target Range |
FDA-Monographed Medications & Public Cash Price Reference for Cholesterolosis
Treatment selection for Cholesterolosis depends on clinical severity, diagnostic lab results, and medical history. Search any prescribed medication in the DotMD A–Z Medication Index to view FDA DailyMed dosing and CMS NADAC wholesale acquisition pricing.
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Cholesterolosis)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| New Insights on Benefits and safety of ongericimab given by prefilled syringe or autoinjector in: What a 255-Participant Study Found In Chinese patients with primary high cholesterol and mixed high cholesterol, a 12-week treatment regimen with ongericimab administered by PFS or AI significantly reduced LDL-C and other lipid parameters, proving to be safe... Nutrition, metabolism, and cardiovascular diseases : NMCD • 2024-09-15 • Phase III Randomized Trial | N = 255 | 93/100 | PMID 38866609 ↗ |
| New Insights on Real-world benefits and safety of atorvastatin and simvastatin in patients with: What a 1,732-Participant Study Found In both comparator groups a higher proportion of atorvastatin-treated patients reached their NCEP LDL cholesterol goal compared with simvastatin. The American journal of cardiology • 2002-03-15 • Randomized Controlled Trial | N = 1,732 | 90/100 | PMID 11897207 ↗ |
| Can This Approach Help? Inside the Latest Research on Benefits and safety of Triple Therapy With Telmisartan, Amlodipine, and Among 148 patients, the changes in msSBP from baseline after 8 weeks of treatment were a mean (SD) of -24.41 (2.38) versus -9.31 (2.36) mm Hg in the telmisartan/amlodipine/rosuvastatin and telmisartan/rosuvastatin groups,... Clinical therapeutics • 2019-02-15 • Phase III Randomized Trial | Multi-cohort | 88/100 | PMID 30665829 ↗ |
| Can This Approach Help? Inside the Latest Research on Ezetimibe in Combination With Simvastatin Reduces Remnant Cholesterol Without Clinical Trial Registration URL : www.clinicaltrialsregister.eu . Journal of the American Heart Association • 2018-12-18 • Randomized Controlled Trial | Multi-cohort | 88/100 | PMID 30561264 ↗ |
| What the Latest Evidence Really Says About Benefits and risks of rosuvastatin versus atorvastatin from a meta-analysis of Percentages of change in GFR improved significantly with both treatments. The American journal of cardiology • 2008-12-15 • Meta-Analysis | Multi-cohort | 86/100 | PMID 19064019 ↗ |
Cholesterolosis Patient Community & “People Like Me” Threads
Filter Cholesterolosis community threads and patient logs by age, biological sex, dosage, and treatment duration.